Form 4: Corbus Pharmaceuticals' Chief Medical Officer Receives Stock Options and Restricted Stock Units

Dominic Smethurst, Chief Medical Officer of Corbus Pharmaceuticals, was granted 50,000 restricted stock units and stock options for 50,000 shares on February 27, 2024.

Summary

• On February 27, 2024, Dominic Smethurst, the Chief Medical Officer of Corbus Pharmaceuticals Holdings, Inc., received 50,000 restricted stock units (RSUs) and an option to purchase 50,000 shares of common stock.
• The RSUs will vest in four equal installments starting on February 27, 2025.
• If Smethurst's employment is terminated without cause after the first vesting date, a pro-rata portion of the RSUs will vest based on completed months of service since the most recent vesting date.
• The stock options have an exercise price of $26.07 and also vest over time, with 25% vesting on February 27, 2025, and the remaining 75% vesting monthly over the following 36 months.
• The option award was made under the company's 2014 Equity Compensation Plan.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of RSUs and stock options aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued service from the Chief Medical Officer.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to attract and retain key executives and align their interests with those of shareholders. The size and vesting schedule of the grants are typical for executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also use stock options and RSUs to incentivize their executives.
• The vesting schedules are generally consistent with industry norms, promoting long-term commitment.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates